
    
      This is a randomized, double-blind, paralleled study. 40 patients will be separated into two
      groups, and receive basic treatment (Aspirin Tablet). Patients in experimental group will
      receive hUC-MSC once a month, total 3 times. After the treatment, investigator will have
      follow-up visit for 6 months, evaluate the security and efficacy of hUC-MSC.
    
  